



**World Health
Organization**

**WHO R&D Blueprint
novel Coronavirus**

**Terms of Reference of the
WHO COVID-19 Infection Prevention and
Control Research Working Group**

WHO reference number

© World Health Organization 2020. All rights reserved.



R&D Blueprint

Powering research
to prevent epidemics



Table of Contents

TABLE OF CONTENTS..... **2**

INTRODUCTION/OBJECTIVES.....ERROR! BOOKMARK NOT DEFINED.

TERMS OF REFERENCE.....ERROR! BOOKMARK NOT DEFINED.

COMPOSITION **4**

EXPERTS..... **ERROR! BOOKMARK NOT DEFINED.**

WHO SECRETARIAT **6**

Ongoing research by IPC participants

Publications by IPC participants



WHO COVID-19 IPC R&D Working Group

Introduction

In February 2020, the World Health Organization Research and Development (R&D) Blueprint in collaboration with the GloPID-R (the Global Research Collaboration for Infectious Disease Preparedness) held the first Global Research and Innovation meeting which was followed by the publication of a roadmap of priorities for research on SARS-CoV-2 in eight areas, one of which was Infection Prevention Control (IPC) with about 50 invited international experts. Following this meeting, all experts interested in continuing to provide input and actively engage in IPC research were invited to form an ongoing working group, that was named WHO COVID-19 IPC R&D Working Group.

The aim of the WHO COVID-19 IPC Research Working Group is to work in concert with the WHO secretariat, other experts and other COVID-19 research working groups with the purpose of facilitating coordination and collaboration of research and innovation in the field of IPC during the response to the COVID-19 pandemic. The participation in the group provides WHO and the group participants with the opportunity to have a protected and confidential forum for sharing of results from ongoing research and gathering expert input for their interpretation. The group has also a critical role in continuing to advance the discussion about the evolving priorities for research in the field of IPC in the context of COVID-19. Finally it identifies the key evidence that is relevant for supporting critical public health and IPC measures to fight against COVID-19 with special focus on protecting health workers and preventing reducing healthcare transmission of SARS-CoV-2 and ultimately of health care associated infections (HAI) and antimicrobial resistance (AMR) in support of all Member States and WHO priorities. The group will also ensure that the needs of low- and middle-income health care settings/countries will be taken into consideration in the development of their protocols and designs.

The terms of reference of the WHO COVID-19 IPC R&D Working Group may change to include other research – not solely restricted to COVID-19 and its focus may change during the course of the epidemic in the event that new priority areas become known and new research is needed.

Objectives

- To promote, support and engage in research into all aspects of IPC of relevance to the COVID-19 pandemic, according to the identified research questions and priorities
- To continue to review and update the global IPC R&D agenda according to the emerging evidence
- To enhance timely sharing of IPC research results and evidence interpretation
- To contribute to the development and implementation science of evidence-based IPC recommendations/documents during the COVID-19 pandemic
- To enhance and provide COVID-19 global outbreak response through provision of evidence-based technical advice
- To dedicate special focus on research areas aimed at improving knowledge and tools to avoid health care-associated transmission of SARS-CoV-2 and to better protect health workers from getting infected with SARS-CoV-2



WHO COVID-19 IPC R&D Working Group

- To contribute to the research agendas of other areas such as social science and epidemiology, in particular for the understanding of the SARS-CoV-2 modes of transmission
- To explore and understand the impact of the COVID-19 pandemic on health care-associated infections and AMR
- To ensure that the needs of low- and middle-income health care settings/countries will be taken into consideration in the development of their protocols and designs.

Long-term objectives may include other research and innovation on IPC, not necessarily related to the COVID-19 response, pending the assessment of the current collaboration and the resources available at WHO for coordinating the group.

Composition of the group

The WHO COVID-19 IPC R&D Working Group aims to ensure representation among its members. Group members bring expertise from across global regions and diversity across the Infection Prevention and Control disciplinary approaches. The group includes members with specific expertise in priority thematic areas of the WHO R&D roadmap for IPC and with cross cutting expertise. Group membership may change during the course of the epidemic in the event that new priority areas become known and new expertise is needed.

Chair: John Conly - Professor of Medicine, Microbiology, Immunology & Infectious Diseases, Pathology & Laboratory Medicine, University of Calgary and Alberta Health Services, Calgary, Alberta, Canada

The chair has the following responsibilities:

- Moderate group activities and discussions to ensure all diverse perspectives are represented.
- To liaise with the WHO focal point and other technical areas as needed.
- Ensure ongoing review and (re-) prioritization of research agenda based on emerging needs and Covid-19 dynamics.
- Promote cross-cutting engagement with other thematic areas and with end-user groups.

WHO secretariat lead: Benedetta Allegranzi

Expert group members

The expert group members have the following responsibilities:

- Provide feedback on “state of the art” Covid-19 IPC evidence and call attention to emerging priority areas
- Conduct IPC research in the context of COVID-19 and confidentially share its results and/or contribute to evidence interpretation
- Respond to requests for evidence and expert guidance to inform response operations via the WHO secretariat



WHO COVID-19 IPC R&D Working Group

- Conduct tasks and develop materials related to delivery or facilitation of the IPC research agenda.
- Share tools, protocols, and (where appropriate) methodological expertise and research outcomes
- Contribute to building networks of IPC experts as well as other relevant disciplines in an effort to ensure global representation for Covid-19.

Members

Alison Holmes	Head of IPC, Imperial College, London, UK
Andreas Voss	Professor of Clinical Microbiology, Canisus-Wilhelmina Ziekenhuis, The Netherlands
Anna Sara Levin	Hospital das Clinicas, Faculdade de Medicina, University of Sao Paulo, Brazil
Barry Cookson	University College London, UK
Ben Cowling	Faculty of Medicine, Hong Kong, China
Ben Park	CDC, US
Dale Fisher	National university of Singapore & GOARN
Diamantis Plachouras	European Centre for Disease Prevention and Control (ECDC)
Fernanda Lessa	Centers for Disease Control and Prevention, US
John Conly	University of Calgary and Alberta Health Services, Calgary, Alberta, Canada
Joost Hopman	MSF lead expert in IPC, Head of IPC and Quality, Radboud University Medical Center, Nijmegen, The Netherlands
Kalisvar Marimuthu	Senior Consultant, Tan Tock Seng Hospital, Singapore
Mark Sobsey	University of North Carolina, Chapel Hill, USA
Mary-Louise McLaws	University of New South Wales, Australia
Mathias Pletz	Professor for Infectious Diseases, Jena University Hospital, Jena, Germany
May Chu	Clinical Professor Colorado School of Public Health, USA



WHO COVID-19 IPC R&D Working Group

Mitchell J. Schwaber	National Center for Infection Control, Israel Ministry of Health
Moi Lin Ling	Director of Infection Control at Singapore General Hospital.
Nalini Singh	Professor of Pediatrics, Global Health, Epidemiology, The George Washington University, Washington, DC, USA
Nina Gobat	Oxford University
Paul Hunter	University of East Anglia, Norwich, UK
Paul Tambyah	Singapore
Sara Tomczyk	Robert Koch Institute
Seto Wing Hong	WHO Collaborating Centre for Infectious Disease Epidemiology and Control, University HK, China
Shaheen Mehtar	Stellenbosch University, Cape Town, South Africa
Tom Jefferson	Senior Associate, University of Oxford
Walter Zingg	Zurich University, Switzerland

WHO Secretariat

Benedetta Allegranzi

April Baller

Alessandro Cassini

Carole Fry

Ying Lin

Madison Moon

Alice Simniceanu

Vicky Willet

Regional Focal Points

Ana Paula Coutinho Rehse - EURO

Joao Paulo de Toledo - PAHO

Maha Ismail Talaat - EMRO



WHO COVID-19 IPC R&D Working Group

Bassim Zayed - EMRO

Landry CIHAMBANYA - AFRO

Howard Sobel - WPRO

Aparnah Singh Shah - SEARO

Masahiro Zakoji - SEARO

Disclaimer

The opinions represented by the participants are not necessarily the opinions or recommendations of WHO.